The 2026 Oral Peptide Wave: What Approved Drugs, NDA Filings and Major Funding Rounds Mean for Research Procurement

Key takeaways

• The FDA approved orforglipron (Foundayo), a non-peptide GLP-1 receptor agonist, on 1 April 2026 — the first oral GLP-1 therapy free of food and water restrictions, and the fastest approval of a new molecular entity since 2002.
• Merck submitted an NDA for enlicitide decanoate (formerly MK-0616), an oral macrocyclic peptide PCSK9 inhibitor, following Phase 3 data published in the New England Journal of Medicine in February 2026.
• JNJ-2113 (icotrokinra, brand name ICOTYDE) — an oral macrocyclic IL-23 inhibitor — was approved in 2026, representing a further proof-of-concept for the macrocyclic peptide class.
• Pinnacle Medicines closed an oversubscribed $89 million Series B in March 2026 for AI-designed oral peptide programmes in immunology and cardiometabolic disease; Syneron Bio closed a $150 million Series B for its macrocyclic peptide platform in April 2026.
• For research-procurement teams, the practical implication is a near-term increase in demand for macrocyclic peptide reference standards, permeation-enhancer formulation inputs, and proteolytic stability assay reagents.

Why oral peptide delivery has been so difficult

The appeal of oral administration for peptide therapeutics has been recognised for well over a century. The obstacles, however, are substantial and well characterised. A March 2026 review in Frontiers in Drug Delivery notes that peptides typically exhibit high polarity, significant charge, large molecular size, and pronounced susceptibility to proteolytic degradation in the gastrointestinal tract — factors that collectively result in low and often insufficient systemic bioavailability. Despite decades of innovation in enteric coatings, enzyme inhibitors, permeation enhancers, nanoparticles, and ingestible devices, most oral peptide programmes have historically failed to achieve regulatory or commercial success.

A concurrent Frontiers review published in March 2026 confirms that oral delivery remains the preferred route for chronic indications because of patient convenience and adherence, but that maximising the clinical and commercial potential of peptide therapeutics requires overcoming inherently unfavourable physicochemical properties.

The industry's response to these constraints has bifurcated into two distinct strategies: small-molecule mimicry (designing synthetic, non-peptide molecules that activate peptide receptors) and macrocyclic peptide engineering (constraining peptide conformation to confer proteolytic resistance and membrane permeability). Both strategies are now producing approved or near-approved drugs, and the distinction between them has important implications for research sourcing.

Orforglipron: a non-peptide solution to a peptide problem

The FDA approved orforglipron, marketed as Foundayo by Eli Lilly, on 1 April 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. According to the FDA's announcement, the approval was issued 50 days after filing — 294 days before the application's PDUFA date — making it the fastest NME approval since 2002, and the first NME approved under the Commissioner's National Priority Voucher pilot programme.

Critically for researchers tracking the oral GLP-1 space, orforglipron is not a peptide. It is a small-molecule, non-peptide GLP-1 receptor agonist that binds and activates GLP-1 receptors — specifically those in brain regions that regulate appetite and caloric intake — without the structural constraints that make peptide-based oral GLP-1 formulations (such as oral semaglutide) subject to strict fasting requirements. Unlike oral semaglutide, orforglipron has no food or water restrictions, a pharmacokinetic advantage that stems from its non-peptide architecture allowing consistent absorption regardless of food intake.

In the Phase 3 ATTAIN-1 study (n=3,127; patients without diabetes), orforglipron demonstrated dose-dependent weight loss of –7.5% to –11.2% versus –2.1% for placebo at 72 weeks. In ATTAIN-2 (n=1,613; patients with type 2 diabetes), weight reductions of –5.1% to –9.6% were observed alongside significant improvements in HbA1c. New Phase 3 ACHIEVE study data presented at the ADA 2026 Scientific Sessions showed orforglipron achieved greater A1c reduction and weight loss than both dapagliflozin and oral semaglutide in patients with type 2 diabetes, though with a somewhat less favourable tolerability profile than semaglutide.

The labelling for Foundayo includes a boxed warning for thyroid C-cell tumours, though orforglipron was not pharmacologically active in rodents and did not produce thyroid tumours in rodent carcinogenicity studies — a distinction from the peptide-based GLP-1 class. One ACHIEVE-5 investigator noted that as a non-peptide compound, orforglipron will be relatively straightforward to produce generically once it goes off-patent, a manufacturing consideration with long-term implications for supply chains.

For procurement teams, the practical consequence is that demand for orforglipron reference standards and in vitro receptor binding assay tools is likely to grow as research groups characterise its pharmacology and compare it with peptide-based GLP-1 agonists.

Enlicitide decanoate: the macrocyclic peptide approach reaches the NDA stage

Whilst orforglipron sidesteps the oral peptide challenge altogether by using a small molecule, Merck's enlicitide decanoate (formerly MK-0616) demonstrates that genuinely peptide-based oral drugs can reach regulatory submission, provided the structural engineering is sufficiently sophisticated.

Enlicitide decanoate is an orally available macrocyclic peptide that inhibits PCSK9 by interfering with the interaction between PCSK9 and the LDL receptor, with an IC50 of approximately 2.5 nM. The molecule comprises eight amino acid residues — six of them non-canonical — alongside two macrocyclic domains, including a 37-membered macrocycle incorporating a non-peptidic fragment. Unlike previous PCSK9 inhibitors, which are monoclonal antibodies requiring parenteral administration, enlicitide is an entirely synthetic molecule that can be taken orally — a distinction with direct implications for patient access and commercial scale.

The Phase 3 CORALreef Lipids trial (n=2,912) was completed in July 2025, with results published in the New England Journal of Medicine on 5 February 2026 (NEJM 2026;394(6):529-539). According to a May 2026 publication in Science, Merck subsequently published landmark work describing the large-scale biocatalytic synthesis of enlicitide decanoate using a tailored enzyme suite, with the paper providing a blueprint for scalable synthesis of complex oral macrocyclic peptides. An NDA has been submitted to the FDA, according to a summary of the fourth Controlled Release Society workshop on oral peptide administration, published in Frontiers in Drug Delivery in May 2026.

The synthesis challenge for enlicitide is illustrative of what distinguishes macrocyclic peptide manufacture from conventional solid-phase peptide synthesis (SPPS). The structural complexity — particularly an ammonium-containing side chain critical for biological activity and its impact on solubility — precluded standard SPPS, requiring a fully modular and convergent manufacturing approach. Procurement teams sourcing macrocyclic peptide reference materials should anticipate that analytical characterisation requirements for such molecules — including high-field NMR, mass spectrometry, and in vitro metabolic stability assays — differ significantly from those applicable to linear peptide standards.

Icotrokinra: an approved oral macrocyclic IL-23 inhibitor

The macrocyclic oral peptide class gained a further approval in 2026 with icotrokinra (JNJ-2113, brand name ICOTYDE) — an oral macrocyclic IL-23 inhibitor developed by Johnson & Johnson for inflammatory skin disease. According to the May 2026 Frontiers workshop summary, JNJ-2113 was approved in 2026, adding to the growing list of approved oral macrocyclic peptides that now includes oral semaglutide (Rybelsus and oral Wegovy) and oral octreotide (Mycappsa). Together, these approvals are shifting the conversation around oral peptide feasibility from theoretical to demonstrated.

Investment capital flows toward oral peptide platforms

The regulatory milestones have coincided with a material uptick in venture financing directed specifically at oral peptide platforms, signalling that investors consider the underlying science sufficiently de-risked to warrant early-stage platform bets.

Pinnacle Medicines closed an oversubscribed $89 million Series B on 26 March 2026. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investor OrbiMed, bringing total funding to $134 million. Proceeds will support advancement of lead programmes through clinical proof of concept, with an initial focus on immunology and cardiometabolic diseases. Pinnacle's proprietary platform integrates physics-based molecular simulations, AI-enabled design tools, and advanced peptide chemistry to confer resistance to enzymatic degradation and enhance intestinal absorption. The company's disclosed pipeline spans asthma, COPD, inflammatory bowel disease, atopic dermatitis, obesity, and cardiovascular indications, with several bispecific peptide programmes also in development.

Syneron Bio closed a $150 million Series B in April 2026. Founded in 2022, the Beijing-based company leverages artificial intelligence through its proprietary Synova macrocyclic peptide platform, and had previously secured a partnership with AstraZeneca worth $75 million in upfront and near-term milestone payments plus up to $3.4 billion in potential development and commercial milestones. The Series B was led by an unnamed international life sciences fund, alongside Decheng Capital, CDH VGC, a subsidiary of the Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, and BioTrack, as well as existing investors.

Macrocyclic peptides have been characterised as a "goldilocks" drug class because of their ability to bridge the gap between small molecules and biologics, enabling targeting of traditionally difficult-to-drug disease pathways. The capital flowing into Pinnacle and Syneron reinforces this assessment: investors are specifically backing the hypothesis that macrocyclic design can solve the oral delivery problem for biologics-class targets.

Implications for UK research-procurement teams

Several procurement-relevant conclusions follow from the 2026 oral peptide landscape:

Reference material demand is shifting. As macrocyclic peptide drug candidates advance toward the clinic, demand for structurally characterised macrocyclic reference standards — including non-canonical amino acid-containing macrocycles — is likely to increase. Suppliers offering certified reference materials with full mass spectrometry confirmation and NMR characterisation will be better positioned to serve this market than those offering only standard linear peptide products.

Analytical complexity increases. Macrocyclic peptides present distinct analytical challenges relative to linear peptides. Their constrained conformations can produce complex NMR spectra, and their non-canonical residues may require bespoke HPLC method development for purity assessment. Labs evaluating macrocyclic peptide candidates should ensure their analytical workflows are configured for molecular weights in the 1,000–2,000 Da range with multiple non-standard residues.

Proteolytic stability assays are becoming standard. The fundamental design goal of macrocyclic peptides is proteolytic resistance. Research groups developing or characterising such compounds will increasingly require validated in vitro stability assays using simulated intestinal fluid with pancreatin, human enterocyte preparations, and liver S9 fractions — reagent categories that procurement teams should anticipate sourcing with greater regularity.

Non-peptide GLP-1 receptor agonists require different assay tools. Orforglipron's non-peptide architecture means that research groups characterising its mechanism or conducting comparative pharmacology studies will require receptor binding assays and signalling pathway reagents configured for a small-molecule interaction with the GLP-1 receptor, rather than the peptide-based tools applicable to semaglutide or liraglutide.

The oral peptide wave is not a single event — it is a multi-year scientific maturation that is now producing approved drugs, regulatory submissions, and the capital infrastructure to sustain further development. For procurement professionals, positioning reagent and reference material sourcing ahead of the clinical demand curve is the practical priority.